Search results
Results From The WOW.Com Content Network
August 15, 2024 at 5:31 PM. (Reuters) - The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell ...
The U.S. Food and Drug Administration first approved the drug in 2017 to treat a type of bladder cancer. Imfinzi won approval for use in mid-stage non-small cell lung cancer a year later.
Osimertinib. Osimertinib, sold under the brand name Tagrisso, [6] is a medication used to treat non-small-cell lung carcinomas with specific mutations. [7][8] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation ...
The FDA decision allows use of the drug, chemically known as capivasertib, in combination with the British drugmaker's older cancer treatment faslodex. The Truqap combination enters a competitive ...
Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [33] Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca. Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after ...
AstraZeneca plc (/ ˌæstrəˈzɛnəkə /) (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2][3][4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
Cediranib. Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. [ 1 ][ 2 ][ 3 ] The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
August 15, 2024 at 4:43 AM. (Reuters) -AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its blockbuster cancer drug Imfinzi a priority review for patients with ...